Sartar Therapeutics
Sartar Therapeutics develops targeted therapies for rare diseases such as sarcoma.
Funding rounds
10/2020, 10/2025
Valuation after latest round
€13.4 million
Springvest's ownership stake
4.0% (31 December 2025)
Sector
Life sciences
